Tibsovo (IVosidenib) Patent Expiration, LOE Window & CMS Spending

Tibsovo (IVosidenib) by Servier: FDA Orange Book core substance LOE 2033-08-19 (last listed 2039-06-07), 0 AB generics, $307.1M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorServier
FDA Application & PathwayN211192 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2033-08-19
Last Listed Patent or Exclusivity Date2039-06-07
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$307.1M
2024 Medicare Part D Spend$265.2M
2024 Medicaid Spend$41.8M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 17.4% 2-yr change)